Endo Par Innovation Co. LLC—better known as EPIC—settled its lawsuit accusing rival drugmaker Belcher Pharmaceuticals LLC and its BPI Labs LLC unit of infringing patents for its blockbuster emergency epinephrine formulations by rolling out a generic version before its patents expired.
EPIC and sister companies Par Pharmaceutical Inc. and Par Sterile Products LLC announced the out-of-court resolution in a June 10 stipulation of dismissal filed in the US District Court for the Middle District of Florida. No terms of the settlement were disclosed.
EPIC sued BPI and Belcher in August 2023 alleging they infringed US Patent Nos. 9,119,876 and 9,295,657 ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.